SOLICITATION NOTICE
Q -- Pharmacologic mitigation of radiation-induced CNS toxicity.
- Notice Date
- 6/26/2018
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC82551-61
- Archive Date
- 7/17/2018
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Jolomi Omatete, Phone: 2402766561
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov
(ELLIOTTK@MAIL.NIH.GOV, jolomi.omatete@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E126, Bethesda, MD 20892, UNITED STATES. Description The Department of Health and Human Services (DHHS), National Institute of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Radiation Oncology Branch (ROB) plans to procure on a sole source basis Fluor-de-Lys SIRT2 fluorometric drug discovery kit and Plate (white) (half-area with non-binding surface) from by Enzo Life Sciences, Inc. at 10 Executive Boulevard, Farmingdale, NY 11735-4710 USA. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 325414 and the business size standard 1,250 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The NCI Radiation Oncology Branch (ROB) have determined that proteomic profiling and hypothesis-driven investigations have identified mediators of acute radiation response in the mature central nervous system that may produce long-term, sustained proteomic alterations leading to neurodegeneration and functional decline. The NCI has evaluated global changes in the brain and have suggested that sirtuin 2 (Sirt2), myelin oligodendrocyte glycoprotein (Mog), Microtubule associated protein tau (Mapt), Synaptosomal associated protein 25kDa (Snap25), and Dynamin 1 (Dnm1) play crucial roles in converting the acute, subcellular radiation response to long-term radiation toxicities. The Radiation Oncology Branch (ROB) focus is on the role of Sirtuin 2 (Sirt2), a class III histone deacetylase, in these processes. The NCI lab has shown that SIRT2 binds and deacetylates beta-catenin in a dose-dependent manner following exposure to ionizing radiation, and regulates expression in the Wnt signaling pathway and the cellular response to radiation-induced stress. SIRT2 regulates radiosensitivity and the DNA-damage response in rodent and human brain, and acts as a mediator of radioresistance in human glioma. These data are being correlated to patient outcomes evaluating serum and urine markers of CNS radiotoxicity that are evaluated by NCI clinical protocol 08-C-0214, Neuropsychological outcome measures in patients receiving whole brain radiation. The NCI plans to screen for inhibitors of Sirt2 that could be used to evaluate radioprotection and/or mitigation from radiation injury in clinical trial. Contractor Requirements 1) The results obtained shall be reproducible. 2) The inhibitors provided with the kit shall be able to inhibit the deacetylase activity of SIRT2. The inhibitors provided with the assay kit as negative controls shall be able to successfully inhibit the activity of SIRT2. 3) The solvent DMSO shall not interfere with either SIRT2 enzyme and/or substrate. The DMSO solvent shall not generate false fluorescence reading when used alone. 4) The assay shall not show any interference from enzyme or substrate alone on the fluorescence readings. 5) One of the known inhibitors of SIRT2 deacetylase activity is the compound, AGK2. The assay shall show successful inhibition of SIRT2 deacetylase activity. 6) The kit shall offer a standard curve to check for the interference of the drug screened with the developer. 7) The acquisition shall include the following: -90 kits of Fluor-de-Lys SIRT2 fluorometric drug discovery assay kit (BML-AK556-0001). -14 sets of white plates (5 plates/set) half-area with non-binding surface (BML-KI584-0001). Period of Performance The period of performance shall be 4-6 weeks from date of award. The NCI and Radiation Oncology Branch (ROB) has conducted previous studies using Fluor-de-Lys SIRT2 kits provided by the proposed Contractor. This kit provided by Enzo Life Sciences is the only one that resulted in inhibition of the deacetylase activity of SIRT2. To achieve the proposed goals, it is important to have reproducibility of results. Thus, Enzo Life Sciences is the only known source that can provide a Fluoro-de-Lys SIRT2 kit to meet the Government's needs at this time. This is not a solicitation for competitive quotations. However, if any interested parties, especially small businesses, believe they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. A copy of the capability statement must be received in the NCI Office of Acquisition on or before 2:30 PM EST on July 2, 2018. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must have valid registration and certification on Sam.gov, www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC82551-61 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC82551-61/listing.html)
- Place of Performance
- Address: 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04968872-W 20180628/180626230955-09a3eb6d48f55c084cac44e442883bbd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |